Kundu Banani, Brancato Virginia, Oliveira Joaquim, Correlo Vitor M, Reis Rui L, Kundu Subhas C
3B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Guimarães, Portugal.
ICVS/3B's-PT Government Associate Laboratory, 4805-017 Guimarães, Portugal.
Bioengineering (Basel). 2021 Jun 10;8(6):83. doi: 10.3390/bioengineering8060083.
Chemotherapeutic resistance is a major problem in effective cancer treatment. Cancer cells engage various cells or mechanisms to resist anti-cancer therapeutics, which results in metastasis and the recurrence of disease. Considering the cellular heterogeneity of cancer stroma, the involvement of stem cells is reported to affect the proliferation and metastasis of osteosarcoma. Hence, the duo (osteosarcoma: Saos 2 and human adipose-derived stem cells: ASCs) is co-cultured in present study to investigate the therapeutic response using a nonadherent, concave surface. Staining with a cell tracker allows real-time microscopic monitoring of the cell arrangement within the sphere. Cell-cell interaction is investigated by means of E-cadherin expression. Comparatively high expression of E-cadherin and compact organization is observed in heterotypic tumorspheres (Saos 2-ASCs) compared to homotypic ones (ASCs), limiting the infiltration of chemotherapeutic compound doxorubicin into the heterotypic tumorsphere, which in turn protects cells from the toxic effect of the chemotherapeutic. In addition, genes known to be associated with drug resistance, such as SOX2, OCT4, and CD44 are overexpressed in heterotypic tumorspheres post-chemotherapy, indicating that the duo collectively repels the effect of doxorubicin. The interaction between ASCs and Saos 2 in the present study points toward the growing oncological risk of using ASC-based regenerative therapy in cancer patients and warrants further investigation.
化疗耐药是有效癌症治疗中的一个主要问题。癌细胞利用各种细胞或机制来抵抗抗癌治疗,这会导致疾病转移和复发。考虑到癌基质的细胞异质性,据报道干细胞的参与会影响骨肉瘤的增殖和转移。因此,在本研究中,将二者组合(骨肉瘤:Saos 2和人脂肪来源干细胞:ASCs)进行共培养,以使用非粘附性凹面来研究治疗反应。用细胞追踪器染色可对球体内的细胞排列进行实时显微镜监测。通过E-钙粘蛋白表达来研究细胞间相互作用。与同型肿瘤球(ASCs)相比,在异型肿瘤球(Saos 2-ASCs)中观察到E-钙粘蛋白表达相对较高且组织紧密,这限制了化疗药物阿霉素渗入异型肿瘤球,进而保护细胞免受化疗药物的毒性作用。此外,已知与耐药相关的基因,如SOX2、OCT4和CD44在化疗后的异型肿瘤球中过表达,表明二者共同抵抗阿霉素的作用。本研究中ASCs和Saos 2之间的相互作用表明,在癌症患者中使用基于ASCs的再生疗法存在越来越大的肿瘤学风险,值得进一步研究。